Genetron Holdings Limited (ADS) is a leading precision oncology company focused on developing and commercializing molecular profiling and diagnostic solutions for cancer patients. With a strong focus on research and innovation, the company aims to revolutionize cancer treatment by providing personalized and targeted therapies based on a patient’s individual genetic profile. With a growing customer base and an expanding portfolio of products, Genetron Holdings Limited is poised to make a significant impact in the field of precision medicine.
